AU Patent

AU2008343813B2 — Inhibitors of PI3 kinase

Assigned to Amgen Inc · Expires 2012-04-12 · 14y expired

What this patent protects

The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt thereof, that inhibit phosphoinositide 3-kinase; Formula (I) methods of treating diseases or conditions, such as cancer, using the compounds; and pharmaceutical compositions containing …

USPTO Abstract

The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt thereof, that inhibit phosphoinositide 3-kinase; Formula (I) methods of treating diseases or conditions, such as cancer, using the compounds; and pharmaceutical compositions containing the compounds.

Drugs covered by this patent

Patent Metadata

Patent number
AU2008343813B2
Jurisdiction
AU
Classification
—
Expires
2012-04-12
Drug substance claim
No
Drug product claim
No
Assignee
Amgen Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.